Veradermics to Discuss Phase 3 Trial Results on Investor Call
Veradermics plans to review topline results from its Phase 3 ‘304’ VDPHL01 trial in males with mild-to-moderate pattern hair loss on an investor call and webcast scheduled for October 19, 2026, at 8:00 a.m. ET.